Literature DB >> 24101046

Signaling control by epidermal growth factor receptor and MET: rationale for cotargeting strategies in lung cancer.

Eric B Haura1, Matthew A Smith.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24101046     DOI： 10.1200/JCO.2013.50.8234

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Authors:  Fernando C Santini; Siddharth Kunte; Alexander Drilon
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.

Authors:  Yun Bai; Jae-Young Kim; January M Watters; Bin Fang; Fumi Kinose; Lanxi Song; John M Koomen; Jamie K Teer; Kate Fisher; Yian Ann Chen; Uwe Rix; Eric B Haura
Journal:  Cancer Res       Date:  2014-10-27       Impact factor: 12.701

3.  MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors.

Authors:  Matthew A Smith; Thomas Licata; Aliya Lakhani; Marileila Varella Garcia; Hans-Ulrich Schildhaus; Vincent Vuaroqueaux; Balazs Halmos; Alain C Borczuk; Y Ann Chen; Benjamin C Creelan; Theresa A Boyle; Eric B Haura
Journal:  Clin Cancer Res       Date:  2017-08-29       Impact factor: 12.531

4.  Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy.

Authors:  Eunjung Kim; Jae-Young Kim; Matthew A Smith; Eric B Haura; Alexander R A Anderson
Journal:  PLoS Biol       Date:  2018-03-09       Impact factor: 8.029

5.  miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling.

Authors:  Cristina Migliore; Elena Morando; Elena Ghiso; Sergio Anastasi; Vera P Leoni; Maria Apicella; Davide Cora'; Anna Sapino; Filippo Pietrantonio; Filippo De Braud; Amedeo Columbano; Oreste Segatto; Silvia Giordano
Journal:  EMBO Mol Med       Date:  2018-09       Impact factor: 12.137
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.